Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enterodiol SCHEMBL31171993 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL31171979 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL11271740 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL31171980 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL120183 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL30334906 | 1.00 | ENPP2 (0.52) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| SCHEMBL23728328 | 0.87 | ENPP2 (0.44) | ENPP2DRD2DRD1TAAR1CYP3A4 | |
| Enterodiol SCHEMBL2806235 | 0.87 | TRPA1 (0.59) | ENPP2DRD2TAAR1CYP3A4MMP1 | |
| Enterodiol SCHEMBL2987870 | 0.85 | OPRK1 (0.52) | DRD2DRD1CHRM2CHRM1CHRM3 | |
| SCHEMBL30851571 | 0.85 | CYP3A4 (0.41) | ENPP2DRD2DRD1TAAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321197-A1 | Polyphenolic Insulin | KIMBALL WESTWARD LLC (US) | 2023-10-12 | — | — | US | disclosed |
| EP-2501735-B1 | NOVEL PHENOLIC PLASTIC RESINS OBTAINED FROM PHENOLIC COMPOUNDS AND MACROMOLECULAR HARDENERS HAVING ALDEHYDE FUNCTIONS | CENTRE NAT RECH SCIENT (FR) | 2016-01-27 | — | — | EP | disclosed |
| US-9040650-B2 | Resins of the phenoplast type obtained from phenolic compounds and from macromolecular hardeners bearing aldehyde functions | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2015-05-26 | — | — | US | disclosed |
| US-9040650-B2 | Resins of the phenoplast type obtained from phenolic compounds and from macromolecular hardeners bearing aldehyde functions | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2015-05-26 | — | — | US | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-20120277396-A1 | NOVEL PHENOLIC PLASTIC RESINS OBTAINED FROM PHENOLIC COMPOUNDS AND MACROMOLECULAR HARDENERS HAVING ALDEHYDE FUNCTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2012-11-01 | — | — | US | disclosed |
| US-20120277396-A1 | NOVEL PHENOLIC PLASTIC RESINS OBTAINED FROM PHENOLIC COMPOUNDS AND MACROMOLECULAR HARDENERS HAVING ALDEHYDE FUNCTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2012-11-01 | — | — | US | disclosed |
| WO-2011140608-A1 | NEUROPSYCHOPHARMACOLOGICAL TREATMENT REGIMES FOR TREATING PSYCHOLOGICAL DISORDERS | KEATING CHARLOTTE L (AU) | 2011-11-17 | — | — | WO | disclosed |
| US-7582677-B2 | Lignan formulations | HORMOS MEDICAL CORP. (FI) | 2009-09-01 | — | — | US | disclosed |
| US-7528166-B2 | Having protected phase II conjugation reactive phenolic hydroxy groups; bioavailability; nutraceuticals, dietary supplements, food products | HORMOS MEDICAL CORPORATION (FI) | 2009-05-05 | — | — | US | disclosed |
| US-7528166-B2 | Having protected phase II conjugation reactive phenolic hydroxy groups; bioavailability; nutraceuticals, dietary supplements, food products | HORMOS MEDICAL CORPORATION (FI) | 2009-05-05 | — | — | US | disclosed |
| US-20070166255-A1 | Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition | GUPTA SHYAM K | 2007-07-19 | — | — | US | disclosed |
| US-7005447-B2 | Food product comprising hydroxymatairesinol | HORMOS NUTRACEUTICAL OY LTD. (FI) | 2006-02-28 | — | — | US | disclosed |
| US-6689809-B2 | HYDROXYMATAIRESINOL, A GEOMETRIC ISOMER OR A STEREOISOMER OR SALT IN COMBINATION WITH CARRIER, USEFUL AS ADDITIVE TO A FOOD PRODUCT, PRESENT EITHER SOLE LIGNAN OR SINGLE COMPONENT OF LIGNAN | HORMOS NUTRACEUTICAL OY LTD. (FI) | 2004-02-10 | — | — | US | disclosed |
| EP-1165537-B1 | HYDROXYMATAIRESINOL IN CANCER PREVENTION | HORMOS NUTRACEUTICAL OY LTD (FI) | 2003-01-22 | — | — | EP | disclosed |
| US-6451849-B1 | USE OF HYDROXYMATAIRESINOL FOR PREVENTION OF CANCERS, NON-CANCER, HORMONE DEPENDENT DISEASES AND CARDIOVASCULAR DISEASES BY HYDROXYMATAIRESINOL, AND A PHARMACEUTICAL PREPARATION, FOOD ADDITIVE AND FOOD PRODUCT COMPRISING HYDROXYMATAIRESINOL | HORMOS NUTRACEUTICAL OY LTD. (FI) | 2002-09-17 | — | — | US | disclosed |
| US-4343796-A | 2,3-Bis-hydroxybenzyl-derivatives | AKZO NV (NL) | 1982-08-10 | — | — | US | disclosed |
| EP-0043150-A1 | Pharmaceutical 2,3 -bis-hydroxybenzyl butane derivatives | AKZO N.V. (NL) | 1982-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ENPP2 81/4885DRD2 1837/4885DRD1 2948/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ENPP2 81/4885DRD2 1837/4885DRD1 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.